Pasar al contenido principal

CRIOGELES ACTIVADOS POR GENES PARA REPARACION DE CARTILAGO

RTI2018-099389-A-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DA CORUÑA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Chondrogenic Differentiation of Human Mesenchymal Stem Cells via SOX9 Delivery in Cationic Niosomes

  • Carballo-Pedrares, Natalia
  • Sanjurjo-Rodríguez, Clara
  • Señarís, José
  • Díaz-Prado, Silvia
  • Rey-Rico, Ana
[Abstract] Gene transfer to mesenchymal stem cells constitutes a powerful approach to promote their differentiation into the appropriate cartilage phenotype. Although viral vectors represent gold standard vehicles, because of their high efficiency, their use is precluded by important concerns including an elevated immunogenicity and the possibility of insertional mutagenesis. Therefore, the development of new and efficient non-viral vectors is under active investigation. In the present study, we developed new non-viral carriers based on niosomes to promote the effective chondrogenesis of human MSCs. Two different niosome formulations were prepared by varying their composition on non-ionic surfactant, polysorbate 80 solely (P80), or combined with poloxamer 407 (P80PX). The best niosome formulation was proven to transfer a plasmid, encoding for the potent chondrogenic transcription factor SOX9 in hMSC aggregate cultures. Transfection of hMSC aggregates via nioplexes resulted in an increased chondrogenic differentiation with reduced hypertrophy. These results highlight the potential of niosome formulations for gene therapy approaches focused on cartilage repair., The work was supported by MICINN [RTI2018-099389-A-100, RYC2018-025617-I] and Xunta de Galicia [ED431F2021/10]., Xunta de Galicia; ED431F2021/10
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Niosomes-Based Gene Delivery Systems for Effective Transfection of Human Mesenchymal Stem Cells

  • Carballo-Pedrares, Natalia
  • Kattar, Axel
  • Concheiro, Ángel
  • Álvarez-Lorenzo, Carmen
  • Rey-Rico, Ana
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract] Gene transfer to mesenchymal stem cells (MSCs) has arisen as a powerful approach to increase the therapeutic potential of this effective cell population. Over recent years, niosomes have emerged as self-assembled carriers with promising performance for gene delivery. The aim of our work was to develop effective niosomes-based DNA delivery platforms for targeting MSCs. Niosomes based on 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA; 0, 7 or 15%) as cationic lipid, cholesterol as helper lipid, and polysorbate 60 as non-ionic surfactant, were prepared using a reverse phase evaporation technique. Niosomes dispersions (filtered or not) and their corresponding nioplexes with a lacZ plasmid were characterized in terms of size, charge, protection, and complexation abilities. DOTMA concentration had a large influence on the physicochemical properties of resulting nioplexes. Transfection efficiency and cytotoxic profiles were assessed in two immortalized cell lines of MSCs. Niosomes formulated with 15% DOTMA provided the highest values of β-galactosidase activity, being similar to those achieved with Lipofectamine®, but showed less cytotoxicity. Filtration of niosomes dispersions before adding to the cells resulted in a loss of their biological activities. Storage of niosomes formulations (for 30 days at room temperature) caused minor modification of their physicochemical properties but also attenuated the transfection capability of the nioplexes. Differently, addition of the lysosomotropic agent sucrose into the culture medium during transfection or to the formulation itself improved the transfection performance of non-filtered niosomes. Indeed, steam heat-sterilized niosomes prepared in sucrose medium demonstrated transfection capability., The work was supported by MICINN [RTI2018-099389-A-100; PID2020-113881RB-I00], Agencia Estatal de Investigación (AEI) Spain, Xunta de Galicia [ED431C 2020/17], and FEDER. A. Rey-Rico acknowledges MICINN for the Ramón y Cajal Fellowship [RYC2018-025617-I] and Universidade da Coruña/CISUG for the funding for open access charge. This project was also funded by the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie Actions grant agreement N° 813440 (ORBITAL–Ocular Research by Integrated Training And Learning), Xunta de Galicia; ED431C 2020/17
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Biomaterial-Assisted Gene Therapy for Translational Approaches to Treat Musculoskeletal Disorders

  • Venkatesan, Jagadeesh Kumar
  • Rey-Rico, Ana
  • Meng, Weikun
  • Cai, Xiaoyu
  • Pons, Françoise
  • Lebeau, Luc
  • Migonney, Véronique
  • Madry, Henning
  • Cucchiarini, Magali
[Abstract] Biomaterial-assisted gene therapy is a promising strategy for the treatment of various musculoskeletal disorders such as those concerning the articular cartilage, bones, tendons and ligaments, and meniscus as it can deliver candidate gene sequences in a spatially and temporally controlled manner in sites of tissue damage over prolonged periods of time that may be required to durably enhance the specific, natural repair mechanisms in vivo in direct, non-invasive procedures that avoid the arduous manipulation and implantation of patient-dependent cells genetically modified in vitro. In the present work, we provide an overview of the most up-to-date approaches and outcomes in experimental, relevant models of such disorders in vivo using biomaterial-guided gene transfer that may be employed in a near future to treat patients during a clinical intervention as a means to achieve an effective, safe, and persistent translational healing of musculoskeletal injuries., Deutsche Forschungsgemeinschaft; DFG VE 1099/1-1, Deutsche Forschungsgemeinschaft; DFG RE 328/2–1, Francia. Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail; EST-2015/1/005, This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG VE 1099/1-1 to JKV and MC; DFG RE 328/2–1 to ARR and MC), the Ministerio de Ciencia e Innovación (RTI2018-099389-A-100 to ARR), the Ministère de la Recherche et de l’Enseignement Supérieur (ANR - TECSAN: LIGART and ACTISURF grants to VM), and the Agence Nationale de Sécurité Sanitaire de l'Alimentation, de l'Environnement et du Travail (ANSES, EST-2015/1/005 to FP and LL).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Development of New Non-viral Systems for Genetic Modification of Senescent Cells

  • López-Seijas, Junquera
  • Miranda-Balbuena, Diego
  • Iglesias-Fente, Alba
  • Sacristán-Santos, Marta
  • Carballo-Pedrares, Natalia
  • Arufe, M.C.
  • Rey-Rico, Ana
  • Fafián-Labora, J.A.
[Abstract] Senescence is a process characterized by a prolonged irreversible cell-cycle arrest. The accumulation of senescent cells in tissues is related to aging and to the development of age-related diseases. Recently, gene therapy has emerged as a powerful tool for treating age-associated diseases by the transference of specific genes into the target cell population. However, the high sensitivity of senescent cells significantly precludes their genetic modification via classical viral and non-viral systems. Niosomes are self-assembled non-viral nanocarriers that exhibit important advantages due to their elevated cytocompatibility, versatility, and cost-efficiency, arising as a new alternative for genetic modification of senescent cells. In this work, we explore for the first time the use of niosomes for genetic modification of senescent umbilical cord-derived mesenchymal stem cells. We report that niosome composition greatly affected transfection efficiency; those formulations prepared in medium with sucrose and containing cholesterol as helper lipid being the most suitable to transfect senescent cells. Moreover, resulting niosome formulations exhibited a superior transfection efficiency with a markedly less cytotoxicity than the commercial reagent Lipofectamine. These findings highlight the potentiality of niosomes as effective vectors for genetic modification of senescent cells, providing new tools for the prevention and/or treatment of age-related diseases., The work was supported by MICINN (RTI2018-099389-A-100; RYC2018-025617-I; RYC2021-032567-I), Xunta de Galicia (ED431F2021/10; ED481D-2021-020), and Spanish National Health Institute Carlos III (PI20/00497). J.L.-S. acknowledges MICINN (FPU20/06176) for her pre-doctoral fellowship grant. J.F.-L. also gives thanks to the InTalent program from UDC-Inditex for the research grant., Xunta de Galicia; ED431F2021/10, Xunta de Galicia; ED481D-2021-020
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Scaffold-Mediated Gene Delivery for Osteochondral Repair

  • Madry, Henning
  • Venkatesan, Jagadeesh Kumar
  • Carballo-Pedrares, Natalia
  • Rey-Rico, Ana
  • Cucchiarini, Magali
[Abstract] Osteochondral defects involve both the articular cartilage and the underlying subchondral bone. If left untreated, they may lead to osteoarthritis. Advanced biomaterial-guided delivery of gene vectors has recently emerged as an attractive therapeutic concept for osteochondral repair. The goal of this review is to provide an overview of the variety of biomaterials employed as nonviral or viral gene carriers for osteochondral repair approaches both in vitro and in vivo, including hydrogels, solid scaffolds, and hybrid materials. The data show that a site-specific delivery of therapeutic gene vectors in the context of acellular or cellular strategies allows for a spatial and temporal control of osteochondral neotissue composition in vitro. In vivo, implantation of acellular hydrogels loaded with nonviral or viral vectors has been reported to significantly improve osteochondral repair in translational defect models. These advances support the concept of scaffold-mediated gene delivery for osteochondral repair., This research was funded by the Deutsche Forschungsgemeinschaft (DFG VE 1099/1-1 to JKV, HM, and MC), the Ministerio de Ciencia e Innovación (RTI2018-099389-A-100 to A.R.-R.), and the Ministerio de Ciencia e Innovación for a Ramón y Cajal Fellowship (RYC2018-025617-I to A.R.-R.)., Deutsche Forschungsgemeinschaft; DFG VE 1099/1-1
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Gene-Activated Hyaluronic Acid-Based Cryogels for Cartilage Tissue Engineering

  • López-Seijas, Junquera
  • Rey-Rico, Ana
  • Carballo-Pedrares, Natalia
  • Miranda-Balbuena, Diego
  • Lamas Criado, Ibán
  • Yáñez, Julián
Financiado para publicación en acceso aberto: Universidade da Coruña/CISUG, [Abstract] Articular cartilage injuries are very frequent lesions that if left untreated may degenerate into osteoarthritis. Gene transfer to mesenchymal stem cells (MSCs) provides a powerful approach to treat these lesions by promoting their chondrogenic differentiation into the appropriate cartilage phenotype. Non-viral vectors constitute the safest gene transfer tools, as they avoid important concerns of viral systems including immunogenicity and insertional mutagenesis. However, non-viral gene transfer usually led to lower transfection efficiencies when compared with their viral counterparts. Biomaterial-guided gene delivery has emerged as a promising alternative to increase non-viral gene transfer efficiency by achieving sustained delivery of the candidate gene into cellular microenvironment. In the present study, we designed hyaluronic acid-based gene-activated cryogels (HACGs) encapsulating a novel formulation of non-viral vectors based on niosomes (P80PX) to promote MSCs in situ transfection. The developed HACG P80PX systems showed suitable physicochemical properties to promote MSCs in situ transfection with very low cytotoxicity. Incorporation of a plasmid encoding for the transcription factor SOX9 (psox9) into HACG P80PX systems led to an effective MSCs chondrogenic differentiation with reduced expression of fibrocartilage and hypertrophic markers. The capacity of the developed systems to restore cartilage extracellular matrix was further confirmed in an ex vivo model of chondral defect., Funding: The work was supported by MICINN [RTI2018-099389-A-100, RYC2018-025617-I], Xunta de Galicia [ED431F2021/10] and Deputación da Coruña [BINV-CS/2022, 2022000021445]. Acknowledgements: We would like to acknowledge Prof. M. Cucchiarini for providing pACP-hsox9 (psox9, bp 6,915). We also thank Biobanco de A Coruña from SERGAS for providing biological samples, BASF (Ludwigshafen, Germany) for supplying the poloxamer 407 and Universidade da Coruña/CISUG for the funding for open access charge., Xunta de Galicia; ED431F2021/10, Deputación da Coruña; BINV-CS/2022, 2022000021445
RUC. Repositorio da Universidade da Coruña
Publicación Tesis doctoral (DoctoralThesis)

Gene-Activated Cryogels for Cartilage Repair, Criogeles activados por genes para reparación de cartílago

  • Carballo-Pedrares, Natalia
[Abstract] The increase in life expectancy associated with developments in the field of medicine has prompted the prevalence of degenerative diseases related to aging. Specifically, articular cartilage is a tissue with a very limited ability to self-repair upon injury due to its avascular and aneural nature. Hence, osteoarthritis (OA) represents the most common cause of long-term pain and physical disability in developed countries. However, none of the current therapeutic options has been able to completely restore the function of hyaline cartilage, generally leading to the formation of fibrocartilage. In this context, gene therapy has emerged as a promising alternative to treat articular cartilage injuries by transferring therapeutic genes into the lesion site. Non-viral vectors represent the safest tools to accomplish this aim as they avoid the main drawbacks of viral carriers, including the risk of eliciting insertional mutagenesis or immune responses in the host. Nonetheless, the existence of several extracellular and intracellular barriers considerably reduced their efficiency compared to their viral counterparts. Noteworthy, the design of gene-activated matrices (GAMs) may help to overcome these issues by promoting a controlled delivery of the candidate genes into the cellular microenvironment. This dissertation focuses on the production of a gene-activated cryogel (G-HACG) based on a combination of non-viral vectors, a shape memory hyaluronic acid based cryogel (HACG) and a source of primary mesenchymal stem cells (MSCs). Developed cryogels systems showed a macroporous structure mimicking the composition of the cartilage extracellular matrix with great biocompatibility and promoting cell proliferation. Various non-viral gene delivery systems based on niosomes were produced and their composition was optimized to obtain high levels of transfection in MSCs with a reduced cytotoxicity. Best niosome formulations were tested as carriers of a plasmid encoding for the transcription factor SOX9 (nioplexes) to promote MSCs chondrogenesis. After refining their composition, nioplexes were firstly incorporated into the cryogels and their release profile and bioactivity profile were monitored. Lastly, MSCs were incorporated into these systems to produce the G-HACG. Effective chondrogenesis of MSCs inside G-HACG was confirmed, showing a reduced expression of fibrocartilage and hypertrophic markers. A similar trend was observed when administrating G-HACG in an ex vivo model of chondral defect, highlighting the potential of the developed systems for restoring cartilage extracellular matrix., [Resumen] El aumento de la esperanza de vida asociado a los avances médicos ha propiciado la prevalencia de enfermedades degenerativas relacionadas con el envejecimiento. En concreto, el cartílago articular es un tejido con una capacidad muy limitada de autorreparación debido a su naturaleza avascular y aneural. Por lo tanto, la osteoartritis (OA) representa la causa más frecuente de dolor a largo plazo y discapacidad física en los países desarrollados. Además, ninguna de las opciones terapéuticas actuales ha sido capaz de restaurarlo por completo, dando lugar generalmente a la formación de fibrocartílago. En este contexto, la terapia génica ha surgido como una alternativa prometedora para tratar las lesiones del cartílago articular mediante la transferencia de genes terapéuticos en el lugar de la lesión. Los vectores no virales son las herramientas más seguras para este fin, evitando los principales inconvenientes de los transportadores virales, como el riesgo de inducir mutagénesis por inserción o de desencadenar una respuesta inmune en el paciente. No obstante, la existencia de barreras extracelulares e intracelulares reduce considerablemente su eficiencia en comparación con sus homólogos virales. El diseño de matrices activadas por genes (GAMs) constituye una alternativa para soslayar dichas barreras a través de la liberación controlada de los genes candidatos en el microambiente celular. Esta tesis abordó la producción de un criogel activado por genes (G-HACG) mediante la combinación de una fuente de vectores no virales, un criogel de ácido hialurónico (HACG) con memoria de forma y una población de células madre mesenquimales (MSCs). Los criogeles desarrollados mostraron una estructura macroporosa que mimetiza la composición de la matriz del cartílago, y una elevada biocompatibilidad capaz de promover la proliferación celular. Se produjeron varios sistemas no virales de liberación de genes basados en niosomas y se optimizó su composición para obtener niveles elevados de transfección en MSCs, con una reducida citotoxicidad. Las mejores formulaciones de niosomas se probaron como vectores de transferencia de un plásmido que codifica para el factor de transcripción SOX9 (nioplejos) en MSCs con el fin de promover su condrogénesis. Después de refinar su composición, los nioplejos se incorporaron a los criogeles y se estudió su perfil de liberación y bioactividad. Por último, para producir las G-HACG se incorporaron las MSCs en dichos sistemas. Los resultados obtenidos confirmaron la condrogénesis efectiva de las MSCs dentro de los G-HACGs, mostrando una expresión reducida de marcadores de fibrocartílago e hipertróficos. Una tendencia similar fue observada cuando se administraron los sistemas en un modelo ex vivo de defecto condral, poniendo de manifiesto el potencial de los sistemas desarrollados para restaurar la matriz extracelular del cartílago., [Resumo] O aumento da esperanza de vida asociado aos avances no campo da medicina provocou a prevalencia de enfermidades dexenerativas relacionadas co envellecemento. En concreto, a cartilaxe articular é un tecido cunha capacidade limitada de autorrepararse debido a súa natureza avascular e aneural. Por isto, a osteoartrite (OA) é a causa máis común de dor a longo prazo e discapacidade física nos países desenvolvidos. Non obstante, ningunha das opcións terapéuticas actuais é capaz de restaurar a cartilaxe hialina, derivando xeralmente na formación de fibrocartilaxe. Neste contexto, a terapia xénica xurdiu como unha alternativa prometedora para tratar as lesións da cartilaxe articular mediante a transferencia de xenes terapéuticos no lugar da lesión. Os vectores non virais son as ferramentas máis seguras para cumprir esta función, xa que evitan os principais inconvenientes dos transportadores virais, incluíndo o risco de inducir mutaxénese por inserción ou de desencadear unha resposta inmune no paciente. Non obstante, a existencia de barreiras extracelulares e intracelulares reduce a súa eficiencia en comparación cos seus homólogos virais. Cabe destacar que o deseño de matrices activadas por xenes (GAMs) pode axudar a superar estes inconvenientes proporcionando unha liberación controlada dos xenes candidatos no microambiente celular. Esta tese centrouse na produción dun crioxel activado por xenes (G-HACG ) baseada na combinación de vectores non virais, un crioxel de ácido hialurónico (HACG) con memoria de forma e unha fonte de células nai mesenquimais (MSCs). Os crioxeles desenvolvidos mostraron unha estrutura macroporosa que mimetizou a composición da matriz extracelular da cartilaxe, e unha alta biocompatibilidade que promoveu a proliferación celular. Producíronse varios sistemas non virais de liberación de xenes baseados en niosomas e optimizouse a súa composición para obter niveis de transfección elevados en MSCs, cunha reducida citotoxicidade. As mellores formulacións de niosomas probáronse como sistemas de transferencia dun plásmido que codifica para o factor de transcrición SOX9 (nioplexos) co fin de promover a condroxénese das MSCs. Os nioplexos seleccionados incorporáronse primeiro nos crioxeles e estudouse o seu perfil de liberación e a súa bioactividade. Por último, para producir as G-HACG incorporáronse as MSCs nos sistemas. Os resultados obtidos confirmaron a condroxénese efectiva das MSCs dentro dos G-HACG, mostrando unha expresión reducida de marcadores de fibrocartilaxe e hipertróficos. Unha tendencia similar observouse ao administrar as G-HACG nun modelo ex vivo de defecto condral, poñendo de manifesto o potencial dos sistemas desenvolvidos para restaurar a matriz extracelular da cartilaxe., During the first period of thesis development (2019-2022), I was supported by a Predoctoral research training contract funded by the Ministry of Science and Innovation (Grant number RTI2018-099389-A100). The last year of this thesis (2022-2023) was funded by Deputación da Coruña (Grant number BINV-CS/2022, 2022000021445), Deputación da Coruña; BINV-CS/2022, 2022000021445